Estradiol Patch Month-by-Month: What to Expect in the First 3 Months
At a glance
- Climara start / 0.025 mg/day once weekly [1]
- Vivelle-Dot start / 0.0375 mg/day twice weekly [2]
- Placement / lower abdomen below the navel or upper buttock; not the breasts [1]
- Progestogen with a uterus / the Climara label says to consider adding one [1]
- Climara trial data / 614 women exposed for 3 months [1]
- Boxed warning / still covers endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [1][2]
Is there a month-by-month timeline?
No. The Climara and Vivelle-Dot labels describe dosing, placement and adverse reactions, not a symptom schedule. Climara's safety data pool 5 trials in which 614 women were exposed to Climara for 3 months. The table also includes 25 hysterectomized women who used Climara 0.025 mg/day for 6 to 24 months in an osteoporosis-prevention study [1]. Vivelle-Dot's label says no trials were conducted with Vivelle-Dot itself; it is described as bioequivalent to Vivelle, and its table lists reactions reported with Vivelle [2].Month 1: starting dose and placement
Climara starts at 0.025 mg/day once weekly; Vivelle-Dot starts at 0.0375 mg/day twice weekly for vasomotor symptoms or vulvar and vaginal atrophy [1][2]. Climara goes on clean, dry skin of the lower abdomen below the navel or upper buttock, not the breasts; the label says to press it firmly for at least 10 seconds [1]. The Climara instructions say to reapply a fallen patch at a different location. If it cannot be reapplied, they say to apply a new patch for the rest of the 7-day interval and to wear only one patch at a time [1]. The Climara label says swimming, bathing or sauna has not been studied and may decrease adhesion and delivery [1].Months 1 to 3: side-effect rates in the Climara trials
The Climara table lists treatment-emergent reactions reported at 5% or more and more often with Climara than placebo (placebo group n=72). The 0.025 mg/day group includes the osteoporosis-study women. Breast pain was 5% at 0.025 mg/day, 8% at 0.05 mg/day, 29% at 0.1 mg/day and 4% on placebo. Headache was 5%, 18%, 13% and 10%. Abdominal pain was 0%, 11%, 16% and 8%. Edema was 0.5%, 13%, 10% and 6% [1]. Reactions reported by 10% or more of Climara users were breast pain, upper respiratory infection, headache, abdominal pain, pain and edema [1]. Climara lists application-site reaction as a postmarketing event, with no trial rate. The Vivelle table says application-site erythema and irritation occurred in 3.2% or less of patients across treatment groups [1][2].Month 3: the review the label describes
The Climara label says dosage adjustment is guided by clinical response and that attempts should be made to taper or discontinue at 3 to 6 month intervals; the Vivelle-Dot label gives the same interval [1][2]. The Climara label says that when estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be considered to reduce endometrial cancer risk, and that a woman without a uterus generally does not need one [1]. The boxed warning says unopposed estrogen raises endometrial cancer risk, and the label says persistent or recurring abnormal genital bleeding should be evaluated [1]. FDA asked makers of menopausal hormone therapies to change boxed warnings on 2025-11-10 [3]. The Climara label (effective 2026-03-26) and the Vivelle-Dot label (effective 2023-11-17) still carry the longer boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [1][2].Frequently asked questions
Will I feel better in the first month?
The Climara and Vivelle-Dot labels do not give a month-by-month schedule for symptom relief, so they cannot predict whether you will feel better in month one, two or three. What the Climara label does report is side-effect rates from its 3-month trials [1].
What is the starting dose?
Climara starts at 0.025 mg per day once weekly [1]. Vivelle-Dot starts at 0.0375 mg per day twice weekly for vasomotor symptoms or vulvar and vaginal atrophy [2].
What side effects were most common in the first 3 months?
In Climara's trial data, breast pain, upper respiratory infection, headache, abdominal pain, pain and edema were reported by 10% or more of users. Breast pain rose with dose, from 5% at 0.025 mg/day to 29% at 0.1 mg/day [1].
Do I need a progestogen with the patch?
The Climara label says that when estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be considered to reduce the risk of endometrial cancer. It says a woman without a uterus generally does not need one [1].
References
- U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
- U.S. National Library of Medicine, DailyMed. Vivelle-Dot estradiol transdermal system (Sandoz) prescribing information. Vivelle-Dot estradiol transdermal system (Sandoz) label
- U.S. Food and Drug Administration. U.S. Food and Drug Administration